A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Adolescents and Children
Latest Information Update: 02 May 2025
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics; Registrational
- Sponsors Gilead Sciences
Most Recent Events
- 30 Oct 2024 Planned End Date changed from 1 Dec 2024 to 1 Sep 2025.
- 30 Oct 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Mar 2025.
- 30 Oct 2024 Status changed from recruiting to active, no longer recruiting.